Related Experiment Video
Updated: Jul 29, 2026
08:43
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
High-grade lymphoma of the bladder visualized on PET
M Mantzarides1, D Papathanassiou, G Bonardel
1Department of Nuclear Medicine of the Army Instruction Hospital of Val de Grace, Paris, France. mednuc.vdg@dial.oleane.com
Clinical Nuclear Medicine
|June 21, 2005
Summary
Furosemide administration improved visualization of bladder lymphoma during F-18 FDG PET scans. This diuretic method enhances radiotracer clearance, aiding pelvic tumor detection in challenging cases.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- F-18 FDG PET is crucial for cancer staging but faces limitations in visualizing pelvic and urinary tract tumors due to physiological radiotracer excretion.
- Physiological excretion of F-18 FDG into the urinary tract can obscure pelvic tumors, complicating accurate staging and diagnosis.
Observation:
- A rare case of primary diffuse large B-cell lymphoma of the bladder wall was identified in an 82-year-old woman.
- Intravenous administration of furosemide was employed to overcome imaging limitations caused by radiotracer excretion.
Findings:
- Furosemide administration significantly increased urine flow, reducing radiotracer concentration in the urinary tract.
- This facilitated clear visualization of the primary diffuse large B-cell lymphoma of the bladder wall, which might have been obscured otherwise.
- The use of furosemide proved to be an easy, safe, and noninvasive method, even in a patient with renal insufficiency.
Implications:
- Furosemide is a valuable adjunct for improving F-18 FDG PET imaging of pelvic and urinary tract tumors, particularly in rare entities like bladder lymphoma.
- Modern PET camera technology, with rapid acquisition and 3D reconstruction, enhances the safety and efficacy of diuretic administration during PET scans.
- This approach offers a practical solution to improve diagnostic accuracy for challenging pelvic malignancies visualized by PET imaging.
